# Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

> **NCT05727839** · PHASE1 · COMPLETED · sponsor: **Immorna Biotherapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Cutaneous Tumor
- Malignant Solid Tumor

## Interventions

- **DRUG:** JCXH-211 Injection

## Key facts

- **NCT ID:** NCT05727839
- **Lead sponsor:** Immorna Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-24
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05727839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05727839, "Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT05727839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*